GLP-1 drugs have revolutionised the treatment of obesity, but the very reason they are effective is also why it's vital to ...

The benefits of naltrexone/bupropion (Mysimba) continue to outweigh its risks, despite ongoing uncertainty about long-term ...

Are we truly on the brink of a cure for obesity? Or could neglecting the root causes risk worsening the very problems we seek ...

US -based pharmaceutical giant Eli Lilly recently launched its weight loss drug Mounjaro in India. Tirzepatide is the generic ...

A Medicine study used artificial intelligence to discover a naturally occurring molecule, specifically, a peptide, that ...

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Gallagher Re, a reinsurance brokerage and risk management services provider, has released a report on the impact of GLP-1 ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

A woman who has endured comments about her weight since she was five lost 3st in three months after taking weight loss drug ...

Within that group, biotechnology giant Amgen (NASDAQ: AMGN) has been the best-performing stock in 2025, returning an ...